GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40823)

  • GC81590 structure
    GC81590Onjisaponin R
    CAS: 1008798-85-3
    Purity: >98.00%

    Onjisaponin R is an α-amylase inhibitor.

  • GC81591 structure
    GC815914,5,6,7-Tetrahydro-1,2-benzoxazole-3-carboxylic acid
    CAS: 90005-77-9
    Purity: >98.00%

    4,5,6,7-Tetrahydro-1,2-benzoxazole-3-carboxylic acid (Compound 244) is an indole compound.

  • GC81592 structure
    GC81592ToP-DNJ
    CAS: 1508303-85-2
    Purity: >98.00%

    ToP-DNJ is a selective endoplasmic reticulum α-glucosidase II ( GluII ) inhibitor with an IC 50 value of 9.0 μM.

  • GC81593 structure
    GC81593Hepcidin-25 (human) TFA
    Purity: >97.00%

    Hepcidin-25 (human) TFA is an iron metabolism modulator and Antimicrobial agent.

  • GC81594 structure
    GC81594TLSC702
    CAS: 748786-57-4
    Purity: >95.50%

    TLSC702 is a human glyoxalase I ( hGLO I ) inhibitor with an IC 50 of 2.0 μM.

  • GC81595 structure
    GC81595BCS12
    CAS: 329719-71-3
    Purity: >99.50%

    BCS12 is a CAIX inhibitor.

  • GC81596 structure
    GC81596SHMT2-IN-1
    Purity: >99.50%

    SHMT2-IN-1 is a potent serine hydroxymethyltransferase 2 ( SHMT2 ) inhibitor with an IC 50 of 1.21 μM and a K D of 10.6 μM.

  • GC81597 structure
    GC81597Momilactone B
    CAS: 51415-08-8
    Purity: >99.00%

    Momilactone B is an inhibitor of α-amylase and α-glucosidase, with an IC 50 of 146.85 μg/mL against Aspergillus oryzae α-amylase and an IC 50 of 612.03 μg/mL against Saccharomyces cerevisiae α-glucosidase.

  • GC81598 structure
    GC81598Emicizumab (Anti-F9 & Factor IX)
    Purity: >99.50%

    Emicizumab (Anti-F9 & Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis.

  • GC81600 structure
    GC81600S-D-Lactoylglutathione
    CAS: 41656-56-8
    Purity: >98.50%

    S-D-Lactoylglutathione (S-Lactylglutathione; (R)-S-Lactoylglutathione) is a multifunctional metabolic intermediate of the glyoxalase system.

  • GC81601 structure
    GC816012-Hydroxymelatonin
    CAS: 229018-17-1
    Purity: >98.00%

    2-Hydroxymelatonin is a major hydroxylated metabolite of Melatonin.

  • GC81602 structure
    GC81602Glucosamine sulfate potassium chloride
    CAS: 1296149-08-0
    Purity: >98.00%

    Glucosamine sulfate potassium chloride is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement.

  • GC81603 structure
    GC816034’-Phosphopantetheine
    CAS: 2226-71-3
    Purity: >97.50%

    4’-Phosphopantetheine is an orally active coenzyme A (CoA) precursor.

  • GC81604 structure
    GC81604ACSL5-IN-1
    Purity: >99.50%

    ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity.

  • GC81605 structure
    GC81605PGK1-IN-1
    CAS: 3093312-81-0
    Purity: >99.50%

    PGK1-IN-1 (Compound 6e) is a potent and selective PGK1 inhibitor ( IC 50 : 33 nM).

  • GC81606 structure
    GC81606DX-8951 Hydroxy-acid sodium
    Purity: >98.50%

    DX-8951 Hydroxy-acid sodium is a prodrug of phosphoramide.

  • GC81607 structure
    GC81607Edutirsen
    CAS: 3034567-90-0
    Purity: >98.50%

    Edutirsen, an antisense oligonucleotide, is a 1-acylglycerol-3-phosphate O-acyltransferase ( PNPLA3 ) synthesis reducer.

  • GC81608 structure
    GC81608SGC-CK1γ-1
    CAS: 3125107-49-2
    Purity: >99.00%

    SGC-CK1γ-1 is a potent and selective probe for the CK1γ subfamily.

  • GC81609 structure
    GC81609YHV98-4
    CAS: 132858-26-5
    Purity: >98.00%

    YHV98-4 is a selective, blood-brain barrier-permeable Hv1 inhibitor with an IC 50 of 0.7 μM.

  • GC81610 structure
    GC81610SK-129
    CAS: 1919889-97-6
    Purity: >98.00%

    SK-129 is a blood-brain barrier-permeable inhibitor of α-synuclein ( αS ) oligomers with a K d of 221 nM.

  • GC81611 structure
    GC81611Nrf2-IN-4 hydrobromide
    Purity: >99.00%

    Nrf2-IN-4 (Compound PhcY) hydrobromide is a Nrf2 inhibitor.

  • GC81612 structure
    GC81612Y1693
    CAS: 2812381-74-9
    Purity: >99.50%

    Y1693 is an orally active RANKL inhibitor with a K d of 5.03 μM for hRANKL.

  • GC81614 structure
    GC81614Zotadirsen
    Purity: >98.00%

    Zotadirsen is the core component of the AOC drug Delpacibart zotadirsen (AOC1044), consisting of a phosphorodiamidate morpholino oligonucleotide (PMO) targeting exon 44 of the dystrophin gene and an SMCC linker.

  • GC81615 structure
    GC81615Isoeugenol- 13 C
    Purity: >98.00%

    Isoeugenol - 13 C (Iso-Eugenol- 13 C) is the 13 C-labeled Isoeugenol.